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ABSTRACT
The majority of ovarian cancer patients relapse after surgical resection. Evidence 
is accumulating regarding the role of surgery in disseminating cancer cells; in 
particular anaesthesia may have an impact on cancer re-occurrence. Here, we have 
investigated the metastatic potential of volatile anaesthetics isoflurane, sevoflurane 
and desflurane on ovarian cancer cells.
Human ovarian carcinoma cells (SKOV3) were exposed to isoflurane (2%), 
sevoflurane (3.6%) or desflurane (10.3%) for 2 hours. Metastatic related gene 
expression profiles were measured using the Tumour Metastasis PCR Array and 
qRT-PCR. Subsequently vascular endothelial growth factor A (VEGF-A), matrix 
metalloproteinase 11 (MMP11), transforming growth factor beta-1 (TGF-β1) and 
chemokine (C-X-C motif) receptor 2 (CXCR2) proteins expression were determined 
using immunofluorescent staining. The migratory capacities of SK-OV3 cells were 
assessed with a scratch assay and the potential role of CXCR2 in mediating the effects 
of volatile anaesthetics on cancer cell biology were further investigated with CXCR2 
knockdown by siRNA.
All three volatile anaesthetics altered expression of 70 out of 81 metastasic 
related genes with significant increases in VEGF-A, MMP-11, CXCR2 and TGF-β genes 
and protein expression with a magnitude order of desflurane (greatest), sevoflurane 
and isoflurane. Scratch analysis revealed that exposure to these anesthetics increased 
migration, which was abolished by CXCR2 knockdown.
Volatile anaesthetics at clinically relevant concentrations have strong effects on 
cancer cell biology which in turn could enhance ovarian cancer metastatic potential. 
This work raises the urgency for further in vivo studies and clinical trials before any 
conclusions can be made in term of the alteration of clinical practice.
INTRODUCTION
The death rate from ovarian cancer in the United 
States is more than double that of any other gynaecological 
malignancy [1, 2]. The poor prognosis is not only due 
to the aggressive nature of this disease but also because 
metastases are often present at the time of diagnosis or 
surgery [3]. It is thought that perioperative factors may 
contribute to cancer recurrence [4]. Surgical procedures 
such as biopsy and resection have been reported 
to disseminate cancer cells into the circulation and 
surrounding tissues [5] and many studies have reported 
that general anaesthesia dampens immune function, which 
is required to eliminate cancer cells [3, 6, 7].
The effect of general anaesthetics on healthy cells or 
tissues in the micro-environment have been investigated 
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for many years and both volatile and intravenous agents 
have been shown to alter miRNA, mRNA and protein 
expressions [7, 8]. A variety of anaesthetics are used for 
cancer resection without their direct cellular effects on 
cancer cells being known. Recent clinical evidence has 
indicated that the choice of anaesthesia and application 
technique could potentially change the long-term 
prognosis of cancer patients. It has been shown that, 
compared to general anaesthesia, epidural anaesthesia 
for surgery to resect colonic cancer is associated with 
improved survival [9]. The latest study indicated an 
association between certain inhalational anesthetics and 
ovarian cancer outcomes [10] It was also reported that 
mortality was increased for patients with melanoma when 
receiving general, rather than local, anesthesia for the 
surgical removal of the tumour [11]. Despite the routine 
use of a variety of anaesthetics in cancer surgery, little 
research has been done to date on cancer cells and the 
molecular mechanism of how cancer cells interact with 
inhalational anaesthetics gas remains largely unknown. It 
has been shown that sevoflurane increases breast cancer 
cell proliferation in vitro[12]. It is therefore crucial to 
investigate the possible effect of anaesthetics on cancer 
cells.
In this study, our aim is to explore whether 
commonly used volatile anaesthetic agents isoflurane, 
sevoflurane and desflurane affect tumour metastasis 
related genes and hence proteins in ovarian cancer cells 
and to further investigate whether the effects (if any) could 
enhance cancer cell migration potential.
RESULTS
Effects of volatile anaesthetics on metastatic gene 
expressions in SK-OV-3 cells
The tumour metastasis PCR array enabled the 
analysis of 81 mRNAs including 5 endogenous control 
candidates after 6 hours of gas exposure (Figure 1). All 
three gases induced changes in the mRNA expression level 
of 70 out of 81 mRNAs (Table 1), but different inhalational 
anaesthetics had distinct effects on changes in the gene 
expression profile (Table 2). In particular, changes induced 
by desflurane were different to those seen with exposure 
to isoflurane and sevoflurane (Figure 1), with desflurane 
leading to greater increases in mRNA. In order to 
validate these array results, qRT-PCR was performed on a 
proportion of the 81 mRNAs in the array analysis (Figure 
2). The array analysis and the qRT-PCR results are well 
correlated. For example; VEGF-A mRNA expressions 
seen with qRT-PCR were 1.00 ± 0.23 (control), 1.10 ± 
0.14 (isoflurane), 1.47 ± 0.07 (sevoflurane) and 1.89 ± 
0.13 (desflurane), and those from array analysis were 
1.00 ± 0.21 (control), 1.09 ± 0.29 (isoflurane), 1.66 ± 0.28 
(sevoflurane) and 2.78 ± 0.49 (desflurane) relative to the 
control. In addition, this analysis revealed that four of the 
mRNA (CXCR2, TGF-β, VEGF-A and MMP11) were 
significantly up-regulated and thus they were chosen for 
further investigation of protein expression.
Effects of volatile anaesthetics on the expression 
of CXCR2, VEGFA, MMP11 and TGF -β1 on 
SKOV3 cells
Molecules such as VEGFA, MMP11 and TGF -β1 
in particular CXCR2 play a very important role on 
cancer progression including ovarian cancer progression 
[13–18] and hence their expressions with or without 
siRNA after anesthetic exposure were further determined. 
The expression of CXCR2 protein after anaesthetic 
gas exposure was increased, compared with naive 
control (Figure 3A). CXCR2 has been shown to be 
overexpressed in ovarian cancer cell lines and to promote 
cancer metastasis [13] and so its role in anaesthetic-
mediated effects on tumour biology was investigated: 
after transfection with CXCR2 siRNA, the post-exposure 
expression of CXCR, was all reduced significantly 
(Figure 3A and 3B). The negative control that was only 
probed with secondary antibody without primary antibody 
confirmed the specificity of the staining (Figure 3C), 
we have also assessed the transfection efficiency with 
western blot analysis and both siRNA transfection reduced 
the CXCR2 expression to the basal level (Figure 3D). 
Similarly, expression of MMP11, VEGF-A and TGF-β1 
were enhanced by volatile anaesthetics and this effect was 
abolished after CXCR2 siRNA treatment (Figure 4).
Effects of volatile anaesthetics on the cell 
migration of SK-OV3
Cell migration, assessed by gap closure, was 
significantly accelerated in the isoflurane, sevoflurane 
and desflurane groups compared to the control at 24 hours 
post-gas exposure, and at 48 hours the percentage of 
closure increased steadily in the anaesthetic groups whilst 
migration in the control group reached a plateau (Figure 
5A and 5B). Significant differences were also observed at 
72 hours post-gas exposure.
CXCR2 siRNA treatment abolished the effects 
of volatile anaesthetics on the cell migration of 
SKOV3
Based on the correlation between CXCR2 
expression and the effects of volatile anaesthetics on 
cancer cells we carried out further investigations to 
evaluate the knock-down effect of CXCR2 on the 
migratory activity of SKOV3 cells (Figure 6A-6E). Cell 
migration in SKOV3 cells was dramatically suppressed 
upon transfection with CXCR2 siRNA in all anaesthetic 
groups compared to the NC and scrRNA groups. In the 
presence of CXCR2 siRNA, desflurane reduced gap 
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closure by 60%, 62% and 38% relative to the scrRNA 
group at 24, 48 and 72 hours respectively (60%, 70% and 
49% relative to the control group).
DISCUSSION
This is the first study to systemically examine the 
change of metastatic gene profile of ovarian cancer cells 
after being exposed to three inhalational anesthetics: 
isoflurane, sevoflurane and desflurane. The findings in 
this study enhanced our understanding of the impact of 
volatile anaesthetics on cancer growth and metastasis 
and provided a novel insight into molecular mechanisms. 
Most importantly, our work supports clinical concern over 
current anaesthetic regimens for cancer patients[4].
Volatile anaesthetic agents are widely used in cancer 
surgery. Whilst their ability to alter the microenvironment 
and protein expression in healthy organs have been 
reported [7], to date only a few retrospective studies 
have indicated that cancer recurrence and metastasis 
after surgery may be linked to anaesthetic technique [3, 
6]. It has been suggested that volatile anaesthetics may 
alter mRNA expression in cancer cells [19]. This study 
confirms that mRNA for CXCR2, VEGF-A, MMP11 
and TGF-β mRNA’s are all significantly increased after 
exposure to volatile anaesthetics, indicating the activation 
of key molecular mediators of metastasis such as cancer 
cell transformation, basement membrane degradation and 
angiogenesis.
Consistent with the profile of metastatic gene 
expression, our study clearly demonstrated the change 
of migration potential after exposure to inhalational 
anaesthetics. Our previous data obtained from prostate 
cancer cells [20], ovarian cancer cells [21] and renal 
carcinoma cells [22] indicated that isoflurane up-
regulates the synthesis of HIF-1α via the PI3K/Akt/
mTOR pathway and promotes the metastatic potential of 
Figure 1: Isoflurane, Sevoflurane and Desflurane alter mRNA expression levels of tumour metastasis genes shown by 
array analysis. SK-OV3 cells were treated with air (N2) or 2% Isoflurane (Iso) or 3.6% sevoflurane or 10.3% Desflurane for 2 hours, and 
then recovered in the normal cell incubator for up to 24 hours. Six hours after exposure analysis of the tumour metastasis PCR array was 
carried out. Unsupervised hierarchical cluster analysis using Euclidean distance from TaqMan low-density arrays. Gas treatment induced 
changes in the expression of 70 out of 81 mRNAs relative to the controls and, in comparison to sevoflurane and isoflurane, desflurane led 
to greater increases in mRNA (N=4). All data is relative to endogenous control, β-Actin. Red and green colours indicate relatively high and 
low expression, respectively.
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Table 1: Change of the expression of the metastatic genes in all the volatile anesthetics treated group 
(Iso = Isoflurane, Sevo = Sevoflurane, Des = Desflurane) compared with the control group
Table 1A: Decrease in all anaesthesia group
Assay Relative change P-value (Q-value) 
 Cont Iso Sevo Des Cont-Iso Cont-Sevo Cont-Des
CDH6 1.000±0.160 0.001±0.000 0.001±0.000 0.001±0.000 <0.001(<0.001) <0.001(<0.001) <0.001(<0.001)
CXCR4 1.000±0.200 0.057±0.016 0.106±0.026 0.068±0.014 <0.001(<0.001) <0.001(<0.001) <0.001(<0.001)
 
Table 1B: Increased in all anaesthesia group
Assay Relative change P-value (Q-value) 
 Cont Iso Sevo Des Cont-Iso Cont-Sevo Cont-Des
NME2 1.000±0.278 2.081±0.265 1.951±0.494 2.624±0.385 0.002(0.005) 0.005(0.012) <0.001(0.001)
SSTR2 1.000±0.434 2.072±0.506 2.770±0.259 3.619±0.922 0.02(0.038) 0.002(0.005) <0.001(0.001)
HPSE 1.000±0.650 1.981±0.510 2.301±0.563 2.567±0.325 0.029(0.051) 0.010(0.021) 0.004(0.010)
TIMP3 1.000±0.191 1.580±0.151 3.004±0.358 5.103±0.589 0.002(0.005) <0.001(<0.001) <0.001(<0.001)
Table 2: Change of the expression of the metastatic genes in the single volatile anesthetics treated group 
(Iso = Isoflurane, Sevo = Sevoflurane, Des = Desflurane) compared with the control group
Table 2A: Increased in Iso group only      
Assay Relative change P-value (Q-value) 
 Cont Iso Sevo Des Cont-Iso Cont-Sevo Cont-Des
CCL7 1.000±0.255 1.606±0.347 0.835±0.105 1.256±0.197 0.016(0.032) 0.625 0.314
        
Table 2B: Decreased in Iso group only      
Assay Relative change P-value (Q-value) 
 Cont Iso Sevo Des Cont-Iso Cont-Sevo Cont-Des
CHD4 1.000±0.133 0.331±0.060 0.741±0.105 1.124±0.166 <0.001(<0.001) 0.067 0.712
        
Table 2C: Increased in Des group only      
Assay Relative change P-value (Q-value) 
Cont Iso Sevo Des Cont-Iso Cont-Sevo Cont-Des
CDH1 1.000±0.504 0.746±0.346 1.443±0.235 4.274±1.809 0.785 0.511 0.003(0.008)
TGFB1 1.000±0.292 1.187±0.292 1.217±0.091 2.788±0.827 0.618 0.451 <0.001(<0.001)
EWSR1 1.000±0.124 0.869±0.215 1.217±0.208 3.664±1.386 0.820 0.731 <0.001(0.001)
NME1 1.000±0.186 0.996±0.228 1.499±0.304 3.155±0.815 1.000 0.116 <0.001(<0.001)
TP53 1.000±0.233 1.063±0.325 1.055±0.158 3.347±0.861 0.994 0.981 <0.001(0.001)
TCF20 1.000±0.255 0.925±0.384 1.276±0.118 3.054±0.280 0.970 0.440 <0.001(0.001)
SMAD2 1.000±0.207 1.315±0.158 1.357±0.213 2.931±0.404 0.146 0.103 <0.001(<0.001)
NME4 1.000±0.105 1.015±0.025 0.868±0.055 2.208±0.436 0.996 0.425 <0.001(<0.001)
(Continued )
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PLAUR 1.000±0.363 1.008±0.215 1.390±0.128 2.206±0.358 0.991 0.202 0.003(0.008)
SRC 1.000±0.098 0.678±0.065 0.783±0.073 2.114±0.789 0.059 0.318 0.001(0.003)
CD82 1.000±0.287 1.748±0.304 1.574±0.564 2.967±1.669 0.139 0.314 0.007(0.015)
HTATIP2 1.000±0.094 0.827±0.236 1.530±0.271 2.731±0.661 0.529 0.090 <0.001(0.001)
FGFR4 1.000±0.225 1.079±0.249 1.169±0.181 2.765±0.524 0.963 0.688 <0.001(<0.001)
CTBP1 1.000±0.210 1.380±0.138 1.128±0.325 2.427±0.585 0.256 0.940 0.001(0.004)
CTNNA1 1.000±0.292 0.685±0.184 0.832±0.127 2.413±0.560 0.174 0.770 0.001(0.003)
CD44 1.000±0.136 0.886±0.234 1.293±0.146 2.395±0.144 0.634 0.183 <0.001(<0.001)
ITGA7 1.000±0.463 1.237±0.386 1.581±0.372 2.237±0.289 0.695 0.209 0.020(0.040)
METAP2 1.000±0.128 0.853±0.256 1.230±0.254 2.153±0.483 0.675 0.652 0.003(0.004)
FN1 1.000±0.271 1.099±0.077 0.681±0.159 2.042±0.353 0.837 0.093 0.001(0.004)
CST7 1.000±0.128 0.935±0.102 1.238±0.199 2.000±0.209 0.884 0.151 <0.001(<0.001)
SET 1.000±0.214 0.953±0.216 1.112±0.162 1.905±0.261 0.985 0.835 0.003(0.007)
MYCL1 1.000±0.173 0.944±0.217 1.064±0.165 1.825±0.417 0.966 0.969 0.006(0.014)
MMP9 1.000±0.174 0.816±0.111 1.133±0.191 1.814±0.313 0.390 0.735 0.002(0.005)
FLT4 1.000±0.098 0.850±0.108 1.179±0.299 1.790±0.232 0.503 0.607 0.001(0.004)
MTSS1 1.000±0.246 0.903±0.157 1.133±0.020 1.786±0.099 0.847 0.576 0.001(0.003)
MMP7 1.000±0.133 1.354±0.417 1.352±0.199 1.749±0.196 0.054 0.095 0.002(0.005)
CTSK 1.000±0.160 0.826±0.154 1.199±0.151 1.621±0.402 0.476 0.521 0.017(0.035)
CDH11 1.000±0.058 0.761±0.109 0.800±0.177 1.589±0.379 0.196 0.293 0.023(0.044)
HRAS 1.000±0.107 1.146±0.268 1.162±0.262 1.588±0.315 0.830 0.765 0.033(0.058)
MYC 1.000±0.127 0.727±0.121 1.164±0.200 1.563±0.283 0.066 0.599 0.012(0.025)
ETV4 1.000±0.090 0.935±0.151 1.313±0.223 1.542±0.218 0.894 0.110 0.007(0.017)
SMAD4 1.000±0.220 1.056±0.206 0.941±0.147 1.519±0.258 0.973 0.986 0.045(0.075)
COL4A2 1.000±0.250 0.994±0.081 1.041±0.171 1.486±0.213 0.999 0.971 0.027(0.050)
NF2 1.000±0.045 0.884±0.125 1.340±0.298 1.478±0.315 0.712 0.162 0.040(0.069)
        
Table 2D: Decreased in Des group only     
Assay Relative change P-value (Q-value) 
 Cont Iso Sevo Des Cont-Iso Cont-Sevo Cont-Des
EPHB2 1.000±0.224 0.942±0.182 0.656±0.130 0.586±0.122 0.980 0.061 0.016(0.032)
    
Table 2E: Decreased in Iso group and increased in Sevo and Des group 
Assay Relative change P-value (Q-value) 
 Cont Iso Sevo Des Cont-Iso Cont-Sevo Cont-Des
MTA1 1.000±0.240 0.616±0.092 1.775±0.259 2.823±0.623 0.030(0.054) 0.007(0.016) <0.001(<0.001)
        
Assay Relative change P-value (Q-value)
Cont Iso Sevo Des Cont-Iso Cont-Sevo Cont-Des
(Continued )
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cancer. CXCR2 has previously been shown to increase cell 
proliferation [23], cancer angiogenesis [13], and promote 
the resistance of cancer cells to conventional treatment 
[24]. Overexpression and binding of CXCL1 and its 
receptor CXCR2 has been shown to promote tumour 
invasion [25–27]. The present study confirms CXCR-2 as 
a novel therapeutic target to control anaesthetic mediated 
effects on ovarian cancer cell biology. Its central role was 
supported by the observation that genetic knockdown 
of CXCR-2 by siRNA abolished the promoting effects 
of inhalational anaesthetics on SK-OV3 migration. This 
is consistent with previous studies which showed that 
tumour growth and invasion was inhibited when CXCR2 
is down-regulated [28, 29]. Also, some previous studies 
indicated a link between CXCR family and VEGF. In 
microenvironment of renal carcinoma cells, VEGF 
expression seemed to be correlated with CXCR expression 
[30]. Clinical outcomes were reported to be related to 
CXCR and VEGF expressions in esophagogastric cancer 
[31] and in lung carcinoma[32].
The loss of responsiveness to inhibitory growth 
signals exerted by TGF-β was previously established in 
ovarian cancer cells [33]. TGF-β has been demonstrated 
to enhance the aggressiveness of ovarian cancer cells [34]. 
All these evidence strongly support our conclusion that up-
regulation of both CXCR2 and TGF-β promote the change 
of ovarian cancer towards a more invasive phenotype.
In this study, both array analysis and 
immunofluorescence data show significant increases 
in expression of MMP11 and VEGF-A which was 
suppressed after CXCR2 siRNA transfection, indicating 
an interaction between CXCR2 and MMP11. Matrix 
metalloproteinases (MMPs) are zinc-dependent 
enzymes capable of degrading extracellular matrix and 
basement membrane components and are involved in 
tumour metastasis [35]. MMP expression in tissue has 
Table 2F: Increased in Sevo and Des group    
Assay Relative change P-value (Q-value) 
 Cont Iso Sevo Des Cont-Iso Cont-Sevo Cont-Des
CXCR2 1.000±0.185 1.792±0.059 2.918±0.235 4.902±1.073 0.139 <0.001(<0.001) <0.001(<0.001)
PTEN 1.000±0.198 1.118±0.309 3.357±0.615 5.566±1.147 0.922 <0.001(<0.001) <0.001(<0.001)
HGF 1.000±0.156 1.446±0.235 2.390±0.483 5.211±1.155 0.094 <0.001(0.001) <0.001(<0.001)
IGF1 1.000±0.262 0.813±0.237 2.139±0.329 4.387±0.693 0.566 0.002(0.005) <0.001(<0.001)
RORB 1.000±0.230 1.465±0.167 1.978±0.348 4.268±0.898 0.052 0.001(0.004) <0.001(<0.001)
TNFSF10 1.000±0.282 0.643±0.081 2.259±0.499 3.961±0.548 0.052 <0.001(0.002) <0.001(<0.001)
CTSL1 1.000±0.142 0.959±0.240 1.684±0.451 3.856±0.603 0.982 0.031(0.055) <0.001(<0.001)
MGAT5 1.000±0.024 1.221±0.250 3.270±0.731 3.813±0.464 0.461 <0.001(<0.001) <0.001(<0.001)
RPSA 1.000±0.159 0.744±0.187 1.756±0.138 3.664±0.637 0.132 0.004(0.010) <0.001(<0.001)
FAT1 1.000±0.133 1.159±0.204 2.233±0.619 3.150±0.958 0.839 0.003(0.008) <0.001(0.001)
TIMP2 1.000±0.335 1.276±0.099 1.517±0.109 3.130±0.447 0.212 0.025(0.046) <0.001(<0.001)
MMP13 1.000±0.070 0.854±0.068 1.539±0.167 2.986±0.406 0.197 <0.001 <0.001(<0.001)
SYK 1.000±0.025 0.973±0.128 1.593±0.246 2.943±0.417 0.982 0.002(0.005) <0.001(<0.001)
KRAS 1.000±0.259 1.210±0.211 1.954±0.263 2.858±0.367 0.419 0.001(0.003) <0.001(<0.001)
VEGFA 1.000±0.214 1.063±0.347 1.612±0.281 2.406±0.619 0.952 0.025(0.046) <0.001(0.001)
IL1B 1.000±0.215 1.300±0.132 2.313±0.510 2.754±0.623 0.290 0.001(0.002) <0.001(0.001)
NR4A3 1.000±0.096 1.008±0.189 1.400±0.189 2.438±0.434 1.000 0.048(0.079) <0.001(<0.001)
MMP11 1.000±0.481 1.170±0.643 1.284±0.141 1.261±0.229 0.184 0.018(0.021) 0.015(0.019)
KISS1R 1.000±0.043 1.205±0.250 1.555±0.211 2.158±0.331 0.413 0.007(0.017) <0.001(<0.001)
DENR 1.000±0.239 1.461±0.327 2.345±0.412 2.089±0.499 0.121 0.001(0.002) 0.002(0.006)
MET 1.000±0.226 1.207±0.085 1.597±0.281 1.961±0.422 0.465 0.022(0.042) 0.002(0.005)
CXCL12 1.000±0.109 1.088±0.228 1.641±0.276 1.826±0.304 0.931 0.008(0.017) 0.002(0.005)
PNN 1.000±0.087 0.986±0.128 1.378±0.208 1.728±0.217 0.997 0.022(0.042) <0.001(0.001)
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been correlated with increased cancer cell proliferation 
and invasion [36]. MMP-11 is frequently found in 
ovarian carcinomas and is involved in ovarian cancer 
invasion [37]. MMP-11 overexpression has also been 
demonstrated to confer a poor prognosis in breast 
carcinomas [38] and was significantly correlated with 
the metastasis of hepatocellular carcinoma [39].
Angiogenesis has been established as a vital 
component in the mechanisms responsible for tumour 
metastasis[40]. Vascular endothelial growth factor 
(VEGF) is a well-known pro-angiogenetic factor[41], 
which stimulates neo-vascularisation and increases 
microvascular permeability[41, 42]. Higher levels of 
VEGF are frequently observed in ovarian carcinomas 
in patients [43] and it has been shown to play a critical 
role in different stages of ovarian cancer development 
and metastasis [44]. An interaction between MMP11 and 
VEGF-A has also been reported [39], and our study clearly 
demonstrated that inhalational anaesthetics promote the 
production of both MMP11 and VEGF-A, enhancing cell 
migration through basement membrane degradation and 
the formation of new vasculature.
Several study have suggested that inhalational 
anaesthetics may affect intracellular calcium homeostasis, 
especially via activation of InsP3R[45, 46]. While the 
intracellular calcium concentration is an important 
regulator of cell growth and death, signal transduction 
and hormone secretion, gene expression for proteins 
such as PI3K/Akt, MAPK, Erk has been shown to be 
involved[46]; however, the exact mechanism in cancer 
cells remains unclear, this certainly warrants further 
investigation in our future studies.
Compared with inhalational anaesthesia, Propofol, 
on the other hand, has been shown to be beneficial for 
the patients after cancer surgery, and studies have shown 
that propofol inhibited the invasion of cancer cells [47]. 
We have also demonstrated that isoflurane induced up-
regulation of HIF-1α and its downstream effectors in 
prostate cell line. However, Propofol decreased HIF-1α 
accumulation induced by hypoxia or even isoflurane-
induced HIF-1α activation, and partially reduced cancer 
cell malignant activities [20].
Our study is not without limitations. Firstly, 
compared to general anaesthesia, the use of regional 
Figure 2: Isoflurane, Sevoflurane and Desflurane alter mRNA expression levels of tumour metastasis genes shown 
by RT-PCR. SK-OV3 cells were treated with air (N2) or 2% isoflurane (Iso) or 3.6% sevoflurane (Sevo) or 10.3% desflurane (Des) for 
2 hours, and then recovered in the normal cell incubator for up to 24 hours. Six hours after exposure analysis of the tumour metastasis 
PCR array was carried out. Results obtained from the tumour metastasis PCR array and RT-PCR analysis are well correlated. All data is 
displayed as relative to the endogenous control, β-Actin (n = 4). Data are expressed as mean ± SD. NC: naïve control. Iso: isoflurane, Sevo: 
sevoflurane, Des: desflurane.
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anaesthesia has been shown to reduce recurrence rates in 
ovarian[6], breast [48] and prostate cancer[3]. However, 
the mechanisms by which tumour cells respond to 
different anaesthetics at a molecular level remain unclear. 
It would be interesting to compare the pattern of the 
change of genetic profile in cell culture exposed to general 
and local anaesthetics. Secondly, the cancer metastatic 
potential was assessed only in a cell culture model 
with one cell line, short time course and single siRNA. 
The kinetics of selected markers in longer time course 
remained unknown. Thirdly, the wound healing assay is 
an established standard protocol to analyse the cancer cell 
migration capability but undoubtedly cell proliferation 
is not exclusive to contribute the outcome. Lastly, there 
could be more anaesthetic effects on cancer cells with 
different dose or time courses, or even nonspecific effects 
of volatile agents. However, one can argue that the cancer 
cell biology changes observed in this study are very likely 
their “intrinsic” pharmacological effects in which it has 
been demonstrated previously that isoflurane effects on 
cancer cell growth and migration were concentration- and 
time-dependent [22]. Further in vivo studies should be 
considered for future investigation to verify these in vitro 
findings. Nevertheless, the work reported here provides 
potentially useful information on the effects of specific 
anaesthetics on cancer cell biology rather than simply 
suggesting a class effect.
CONCLUSIONS
Together, our results suggest that volatile anaesthetics 
promote changes in the expression of metastatic genes and 
proteins. This study strongly suggests that inhalational 
anaesthetics have a distinct and profound effect on cancer 
growth and its capacity to metastasise. In addition, this 
study provides novel insights into molecular mechanisms 
and could lead to the identification of new anaesthetic 
regimens for cancer patients during surgery. However, this 
area of research into the potential impact of anaesthetics on 
cancer biology is just beginning, and extensive preclinical 
and clinical studies are warranted before any decisions can 
be made to change current clinical practice.
Figure 3: Expression of CXCR2 is increased in ovarian cancer upon exposure to volatile anaesthetics. SK-OV3 cells 
were treated with air (N2) or 2% isoflurane (Iso) or 3.6% sevoflurane or 10.3% desflurane for 2 hours, and then recovered in the normal 
cell incubator for up to 24 hours. CXCR2 siRNA or scrambled siRNA was administered 6 hours before the gas exposure. Expression 
of A. CXCR2 (red) was assessed with immunofluorescent staining (nuclei counter-stained with DAPI) at 24 hour after gas exposure. 
Statistical analysis of fluorescent intensity of B. CXCR (n = 8). C. Negative control (secondary antibody with no primary antibody is 
added) demonstrated the specificity of the staining. D. Western blotting analysis of CXCR2 and GAPDH (n=4). Data are expressed as 
mean ± SD. *p<0.05 and ***p<0.001. Scale bar: 10μm. NC: naïve control. Iso: isoflurane. Sevo: sevoflurane, Des: desflurane. Scr Si: 
Scrambled siRNA, C Si: CXCR2 SiRNA. #: comparison between air and anaesthetic treated cells, *comparison between scrambled siRNA 
and CXCR2 siRNA treated cells.
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Figure 4: Upregulation of VEGF-A, MMP11 and TGF-β in ovarian cancer cells upon exposure to volatile anaesthetics. 
SK-OV3 cells were treated with air (N2), 2% isoflurane (Iso) or 3.6% sevoflurane or 10.3% desflurane for 2 hours, and then recovered in the 
normal cell incubator for up to 24 hours. CXCR2 siRNA or scrambled siRNA was administered 6 hours before the gas exposure. Expression 
of A. MMP-11 (red), C. VEGF-A (red) and E. TGF-β (red) was assessed with immunofluorescent staining (nuclei counter-stained with 
DAPI) at 24 hour after gas exposure. Statistical analysis of fluorescent intensity of B. MMP-11, D. VEGF-A, and F. TGF-β (n = 8). Data are 
expressed as mean ± SD. *p<0.05 and ***p<0.001. Scale bar: 50μm. NC: naïve control. Iso: isoflurane. Sevo: sevoflurane, Des: desflurane. 
Scr Si: Scrambled siRNA, C Si: CXCR2 SiRNA. #: comparison between air and anaesthetic treated cells, *comparison between scrambled 
siRNA and CXCR2 siRNA treated cells.
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Figure 5: Migration of SKOV3 cells is increased after exposure to volatile anaesthetics. SK-OV3 cells were treated with 
air (N2) or 2% isoflurane (Iso) or 3.6% sevoflurane or 10.3% desflurane for 2 hours, and then recovered in the normal cell incubator for 
up to 72 hours. CXCR2 siRNA or scrambled siRNA was administered 6 hours before the gas exposure. A. Cell migration at 0, 24, 48 and 
72 hours after gas exposure, assessed by scratch assay (wound healing assay). B. % healing (gap closure) after gas exposure (n=8). Data 
are expressed as mean ± SD, *p<0.05, **p<0.01 and ***p<0.001. NC: naïve control. Iso: isoflurane, Sevo: sevoflurane, Des: desflurane.
Figure 6: CXCR-2 siRNA abolished effects of inhalational anaesthetics on SK-OV3 cell migration. SK-OV3 cells were 
treated with air (N2) or 2% isoflurane (Iso) or 3% sevoflurane or 10.3% desflurane for 2 hours, and then recovered in the normal cell 
incubator for up to 72 hours. A. Cell migration at 0, 24, 48 and 72 hours after gas exposure, assessed by scratch assay (wound healing 
assay). B, C, D, E. % healing (gap closure) after gas exposure (n=8). Data are expressed as mean ± SD, *p<0.05, **p<0.01 and ***p<0.001. 
NC: naïve control. Iso: isoflurane, Sevo: sevoflurane, Des: desflurane. Scr Si: Scrambled siRNA, C Si: CXCR2 SiRNA.
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Table 3: Primer sequence for PCR
 Forward primer sequence Reverse primer sequence
GenBank/EMBL 
association No.
Nucleotide 
No.
r2 efficiency
Actin β
5'-AGAGCTACGA 
GCTGCCTGAC-3'
5'-AGCACTGTGT 
TGGCGTACAG-3' NM_001101.3 797-980 0.99979 0.98
CXCR2 5'-ACATGGGCAA CAATACAGCA-3'
5'-TGAGGACGAC 
AGCAAAGATG-3' NM_001557.3 1014-1193 1.00000 0.94
MMP 11
5'-GACGGACCTC 
ACCTACAGGA-3'
5'-CAGTACCTGGC 
GAAGTCGAT-3' NM_005940.3 343-510 0.99998 0.94
TGF β1
5'-CAACAATTCCT 
GGCGATACC-3'
5'-GAACCCGTTGA 
TGTCCACTT-3' NM_000660.4 1407-1599 0.99981 1.24
VEGFA 5'-CTACCTCCACC ATGCCAAGT-3'
5'-CACACAGGATG 
GCTTGAAGA-3' NM_001171630.1 1086-1272 0.99982 0.92
MATERIALS AND METHODS
Cell culture
Human ovarian epithelial carcinoma cell line SK-
OV3 (European Cell Culture Collection) was used for 
this study. Cell cultures were kept at 37°C in a humidified 
atmosphere containing 5% CO2. SK-OV3 cells were 
cultured in McCoy’s 5A medium (Sigma-Aldrich, Dorset, 
UK), containing 10% foetal bovine serum (Thermo 
Scientific, Epsom, UK), 2mM L-glutamine and 1% 
penicillin (Sigma-Aldrich, Dorset, UK) and maintained in 
a humidified incubator at 37°C with a 5% CO2 atmosphere.
Test gas exposure
Cells were placed in a purpose-built 1.5L airtight 
gas chamber, equipped with inlet and outlet valves and 
an electric fan to ensure an even distribution of gases 
throughout the exposure period. All gases (BOC, South 
Humberside, UK) were delivered to the gas chamber at a 
rate of 2L/min for a maximum of 5mins until the desired 
gas and anaesthetic concentrations were achieved. The 
chamber gases were monitored using an anaesthetic 
analyser (Datex-Ohmeda, Stirling, UK) until the chamber 
was sealed. The chamber was then placed in an incubator 
(Galaxy R CO2 chamber; New Brunswick Scientific, 
Enfield, USA) at 37°C for the duration of the 2 hour 
incubation. The experimental gas mixtures were 21% 
oxygen, 5% carbon dioxide and 2% isoflurane, 3.6% 
sevoflurane or 10.3% desflurane, balanced with nitrogen. 
The equal 1.7 minimum alveolar concentrations (MAC) 
in human of these volatile anaesthetic concentrations was 
used in this study. After exposure, cultures were returned 
to the normal culture incubator for further study.
RNA extraction
At 6 hours after gas exposure, total RNA was 
extracted from each 60mm dish using the RNeasy mini kit® 
and QIAshredder (QIAGEN, West Sussex, UK) according 
to the manufacturer’s instructions. RNA quantity and 
quality were assessed using a BioPhotometer (Eppendorf, 
Stevenage, UK). Samples with an A260/A280 ratio above 
1.8 were considered of sufficient quality for further analysis.
Array
Array analysis was performed using a Tumour 
Metastasis PCR Array (Qiagen) according to the 
manufacturer’s instructions. The RT2 First Strand Kit 
(Qiagen) was used to produce complementary DNA 
(cDNA) from total RNA. cDNA samples were mixed with 
RT2 SYBR® Green ROX qPCR (Qiagen) before loading into 
each well of the PCR Array. PCR array plates were processed 
and analysed with the 7900HT Fast Real-Time PCR system 
relative quantitation software (Applied Biosystems, LLC, 
Foster City, USA). mRNA expression relative to β-actin 
mRNA was determined using the comparative 2−ΔΔCT (using 
online software provided by Qiagen) method and these 
values were subsequently converted into heat maps (relative 
levels of mRNA expression).
qRT-PC
Gene expression was quantified using the Rotor-
Gene Q system (Qiagen) in the presence of SYBR 
green (Qiagen). cDNA was mixed with master mix, 
forward and reverse primers each and of probe. Paired 
oligonucleotide primers were designed for vascular 
endothelial growth factor A (VEGF-A), matrix 
metalloproteinase 11 (MMP-11), transforming growth 
factor beta-1 (TGFβ1), chemokine (C-X-C motif) receptor 
2 (CXCR2) and β-actin using Primer Designer (Scientific 
and Educational Software, Durham, USA) against the 
sequence downloaded from GenBank and were supplied 
by Invitrogen. The primer sequences, r2 values and 
efficiencies are summarised in Table 3. All TaqMan probes 
were supplied by Qiagen. All mRNA data were expressed 
relative to the endogenous control gene β-actin.
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In vitro siRNA transfection
Cells were seeded in 6-well plates at 60-80% 
confluency, allowed to settle for 24 hours and then 
transfected with scrambled siRNA (ScrRNA) or two 
different CXCR2 siRNA constructs (siRNA1: Sense 
Strand 5’→ 3’- CAGUCAGGAUUUAAGUUUATT; 
5’→ 3’- UAAACUUAAAUCCUGACUGGG. siRNA2: 
5’→ 3’- CCUCAAGAUUCUAGCUAUATT; 5’→ 3’- 
UAUAGCUAGAAUCUUGAGGAG) (Qiagen, Crawley, 
West Sussex, UK) at a concentration of 20nM. The 
transfection was facilitated with HiPerfect Transfection 
Reagent (Qiagen). After 6 hours of transfection, the 
solution was replaced with medium before exposure to test 
gas mixtures. Then cells treated with siRNA1 or with both 
siRNA 1 and 2 will be used for in situ immunostaning and 
western blot respectively (see below).
Scratch assay (wound healing) assay
Cells were seeded into 60mm Petri dishes and 
subsequently scratched before exposure to the test gas 
mixture, after which cells were incubated for 24 hours. 
The scratch assay (wound healing assay) was performed 
for assessing tumour cell migration as previously 
described[49]. One artificial gap per well was scratched 
into the monolayers with a sterile plastic 1000μL 
micropipette tip to generate a uniform gap that was 
devoid of adherent cells. Cells were washed with PBS to 
remove cell debris. Closure of the scratch was monitored 
using an inverted microscope at 4x objective and digital 
camera (Olympus CK30-SLP, Japan) at 0, 24, 48 and 
72 hours after gas exposure and analysed using Image 
J 1.46 software (National Institute of Health, Maryland, 
USA). Gap closure (healing) was quantified as the mean 
percentage of the remaining cell-free area compared with 
the area of the initial wound[50].
Immunostaining
Cells were fixed in 4% paraformaldehyde for 10mins, 
rinsed in PBS (Sigma-Aldrich, Dorset, UK) two times 
for 5min, permeabilised with 0.1% Triton X-100 in PBS 
(PBS-T) for 10min and washed twice for 5min. Blocking 
was carried out at room temperature for 1hr using 10% 
normal donkey serum. Cells were then incubated overnight 
at 4°C in blocking solution containing one of the following 
antibodies: mouse anti- VEGF-A (1:200, Abcam plc, 
Cambridge, United Kingdom), rabbit anti-MMP-11 (1:200, 
Abcam plc, Cambridge, United Kingdom), rabbit anti-
TGF-β (1:200, Abcam plc, Cambridge, United Kingdom) 
and rabbit anti–CXCR2 (1:200, Abcam plc, Cambridge, 
United Kingdom) followed by Rhodamine-conjugated or 
fluorescein isothiocyanate (FITC)-conjugated secondary 
antibody incubation (Millipore, Watfield, UK). Finally, the 
coverslips were mounted onto glass slides with Vectashield 
mounting medium containing DAPI (Millipore). Cells were 
viewed under the Olympus BX60 (Olympus, Hamburg, 
Germany) wide-field fluorescence microscope under a 
20X objective using the appropriate filter. Images were 
captured using a cooled Zeiss AxioCam camera with Zeiss 
software. Images for quantification were pre-processed 
using Image J 1.46 software background subtraction 
(National Institutes of Health, Maryland, USA). All images 
were captured at identical exposure settings. Cells were 
measured by manual tracking and the mean pixel intensity 
was calculated.
Western blot
This was done with our established protocol[20]. 
Briefly, after electrophoresis and transferred onto a 
polyvinylidenedifluoride (PVDF) membrane using the 
iBlot® 2 Dry Blotting System (Invitrogen). Membranes 
were blocked with 5% non-fat powdered milk in Tris-
Buffered Saline with Tween (TBS-T) for 1h at room 
temperature, and then incubated overnight at 4°C with 
anti-CXCR2 rabbit primary antibody (Abcam, 1:500) 
followed by horseradish peroxidase (HRP)-linked anti-
rabbit secondary antibody (Cell Signaling; 1:1000) 
for 1 hour. Protein bands were visualised using the 
enhanced chemiluniscence (ECL) system (Santa Cruz, 
USA) and the Syngene GeneSnap software (Syngene, 
UK). Densitometry analysis was carried out using the 
corresponding GeneTools software (Syngene) and 
presented as a ratio of the protein of interest to a control 
housekeeping protein for analysis.
Statistical analysis
All numerical data is expressed as mean ± SD. One-
way ANOVA analysis followed by post-hoc Tukey’s test 
were applied for most of the analysis using Prism ver5.0 
(GraphPad Software, Inc., California, USA), unless 
otherwise specified. To validate array data, the results 
from array and single qRT-PCR analysis of mRNAs were 
examined using the paired t-test. For analysing our array 
results, the false discovery rate was used as described as 
described previously[51], the false discovery rate (q-value) 
was set at 0.1 using the program QVALUE 2.0 (http://
genomics.princeton.edu/storeylab/qvalue/). P values of 
less than or equal to 0.05 were taken to indicate statistical 
significance.
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